Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease

详细信息    查看全文

• 作者：Rong Fu (1)
  Hui Liu (1)
  Sijie Zhao (1)
  Yihao Wang (1)
  Lijuan Li (1)
  Shan Gao (1)
  Erbao Ruan (1)
  Guojin Wang (1)
  Huaquan Wang (1)
  Jia Song (1)
  Zonghong Shao (1)
  
  1. Department of Hematology ; Tianjin Medical University General Hospital ; 154 Anshao Street ; Heping District ; Tianjin ; 300052 ; PR China
  
• 关键词：Chemokine cytokine ligand 3 ; Myeloma bone disease ; Osteoblast ; Runx2 ; Osterix
• 刊名：Cancer Cell International
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：14
• 期：1
• 全文大小：2,033 KB
• 参考文献：1. Taube, T, Beneton, MNC, McCloskey, EV, Rogers, S, Greaves, M, Kanis, JA (1992) Abnormal bone remodeling in patients with myelomatosis and normal biochemical indices of bone resorption[J]. Eur J Haematol 49: pp. 192-198 CrossRef
  2. Roodman, GD, Choi, SJ MIP-1 Alpha and Myeloma Bone Disease. In The Biology of Skeletal Metastases. In: Keller, ET, Leland WK, C eds. (2004) Cancer Treatment and Research Volume 118. Springer, US, pp. 83-100
  3. Terpos, E, Politou, M, Szydlo, R, Goldman, JM, Apperley, JF, Rahemtulla, A (2003) Serum levels of macrophage inflammatory protein - 1 alpha (MIP - 1伪) correlate with the extent of bone disease and survival in patients with multiple myeloma[J]. Br J Haematol 123: pp. 106-109 CrossRef
  4. Hata, H (2005) Bone lesions and macrophage inflammatory protein-1 alpha (MIP-1伪) in human multiple myeloma[J]. Leuk Lymphoma 46: pp. 967-972 CrossRef
  5. Lentzsch, S, Chatterjee, M, Gries, M, Bommert, K, Gollasch, H, Dorken, B, Bargou, RC (2004) PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells[J]. Leukemia 18: pp. 1883-1890 CrossRef
  6. Lentzsch, S, Gries, M, Janz, M, Bargou, R, Dorken, B, Mapara, MY (2003) Macrophage inflammatory protein 1-alpha (MIP-1伪) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells[J]. Blood 101: pp. 3568-3573 CrossRef
  7. Heider, U, Hofbauer, LC, Zavrski, I, Kaiser, M, Jakob, C, Sezer, O (2005) Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease[J]. Biochem Biophys Res Commun 338: pp. 687-693 CrossRef
  8. Han, JH, Choi, SJ, Kurihara, N, Koide, M, Oba, Y, Roodman, GD (2001) Macrophage inflammatory protein-1伪 is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor 魏B ligand[J]. Blood 97: pp. 3349-3353 CrossRef
  9. Silvestris, F, Cafforio, P, Matteo, M, Calvani, N, Frassanito, MA, Dammacco, F (2008) Negative regulation of the osteoblast function in multiple myeloma through the repressor gene E4BP4 activated by malignant plasma cells[J]. Clin Cancer Res 14: pp. 6081-6091 CrossRef
  10. Silvestris, F, Lombardi, L, Matteo, M, Bruno, A, Dammacco, F (2007) Myeloma bone disease: pathogenetic mechanisms and clinical assessment[J]. Leuk Res 31: pp. 129-138 CrossRef
  11. Roodman, GD (2004) Pathogenesis of myeloma bone disease[J]. Blood Cell Mol Dis 32: pp. 290-292 CrossRef
  12. Fu, R, Gao, S, Peng, F, Li, J, Liu, H, Wang, H, Xing, L, Shao, Z (2014) Relationship between abnormal osteoblasts and cellular immunity in multiple myeloma. Cancer Cell International 14: pp. 62 CrossRef
  13. Qiang, YW, Barlogie, B, Rudikoff, S, Shaughnessy, JD (2008) Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma[J]. Bone 42: pp. 669-680 CrossRef
  14. Wang, YH, Liu, Y, Buhl, K, Rowe, DW (2005) Comparison of the Action of Transient and Continuous PTH on Primary Osteoblast Cultures Expressing Differentiation Stage鈥怱pecific GFP[J]. J Bone Miner Res 20: pp. 5-14 CrossRef
  15. Green, S, Chambon, P (1986) Carcinogenesis: a superfamily of potentially oncogenic hormone receptors[J]. Nature 324: pp. 615-617 CrossRef
  16. Barnes, MJ (1975) Function of ascorbic acid in collagen metabolism[J]. Ann N Y Acad Sci 258: pp. 264-277 CrossRef
  17. Bellows, CG, Aubin, JE, Heersche, JN, Antosz, ME (1986) Mineralized bone nodules formedin vitro from enzymatically released rat calvaria cell populations[J]. Calcif Tissue Int 38: pp. 143-154 CrossRef
  18. Anderson, RE, Kemp, JW, Jee, WS, Woodbury, DM (1984) Ion-transporting ATPases and matrix mineralization in cultured osteoblastlike cells[J]. In Vitro 20: pp. 837-846 CrossRef
  19. Bataille, R, Chappard, D, Marcelli, C, Dessauw, P, Sany, J, Baldet, P, Alexandre, C (1989) Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease[J]. J Clin Oncol 7: pp. 1909-1914
  20. Silvestris, F, Cafforio, P, Tucci, M, Grinello, D, Dammacco, F (2003) Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease[J]. Br J Haematol 122: pp. 39-52 CrossRef
  21. Fuller, K, Owens, JM, Chambers, TJ (1995) Macrophage inflammatory protein-1 alpha and IL-8 stimulate the motility but suppress the resorption of isolated rat osteoclasts[J]. J Immunol 154: pp. 6065-6072
  22. Kukita, T, Nomiyama, H, Ohmoto, Y, Kukita, A, Shuto, T, Hotokebuchi, T, Sugioka, Y, Miura, R, Iijima, T (1997) Macrophage inflammatory protein-1 alpha (LD78) expressed in human bone marrow: its role in regulation of hematopoiesis and osteoclast recruitment[J]. Laboratory Invest 76: pp. 399-406
  23. Tsubaki, M, Kato, C, Manno, M, Ogaki, M, Satou, T, Itoh, T, Kusunoki, T, Tanimori, Y, Fujiwara, K, Matsuoka, H, Nishida, S (2007) Macrophage inflammatory protein-1伪 (MIP-1伪) enhances a receptor activator of nuclear factor 魏B ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways[J]. Mol Cell Biochem 304: pp. 53-60 CrossRef
  24. Olsen, BR, Reginato, AM, Wang, W (2000) Bone development[J]. Annu Rev Cell Dev Biol 16: pp. 191-220 CrossRef
  25. Vallet, S, Pozzi, S, Patel, K, Vaghela, N, Fulciniti, MT, Veiby, P, Hideshima, T, Santo, L, Cirstea, D, Scadden, DT, Anderson, KC, Raje, N (2011) A novel role for CCL3 (MIP-1伪) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function[J]. Leukemia 25: pp. 1174-1181 CrossRef
  26. Komori, T (2007) Regulation of bone development and maintenance by Runx2[J]. Front Biosci: a journal and virtual library 13: pp. 898-903 CrossRef
  27. Nishio, Y, Dong, Y, Paris, M, O鈥橩eefe, RJ, Schwarz, EM, Drissi, H (2006) Runx2-mediated regulation of the zinc finger Osterix/Sp7 gene[J]. Gene 372: pp. 62-70 CrossRef
  28. Gao, Y, Jheon, A, Nourkeyhani, H, Kobayashi, H, Ganss, B (2004) Molecular cloning, structure, expression, and chromosomal localization of the human Osterix (SP7) gene[J]. Gene 341: pp. 101-110 CrossRef
  29. Hill, TP, Sp盲ter, D, Taketo, MM, Birchmeier, W, Hartmann, C (2005) Canonical Wnt/尾-catenin signaling prevents osteoblasts from differentiating into chondrocytes[J]. Dev Cell 8: pp. 727-738 CrossRef
  30. Glass, DA, Bialek, P, Ahn, JD, Starbuck, M, Patel, MS, Clevers, H, Taketo, MM, Long, F, McMahon, AP, Lang, RA, Karsenty, G (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation[J]. Dev Cell 8: pp. 751-764 CrossRef
  31. Gaur, T, Lengner, CJ, Hovhannisyan, H, Bhat, RA, Bodine, PV, Komm, BS, Javed, A, Wijnen, AJ, Stein, JL, Stein, GS, Lian, JB (2005) Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression[J]. J Biol Chem 280: pp. 33132-33140 CrossRef
  
• 刊物主题：Cancer Research; Cell Biology;
• 出版者：BioMed Central
• ISSN：1475-2867

文摘

Background Multiple myeloma is a hematologic malignancy characterized by the accumulation of monoclonal plasma cells in the bone marrow. A common manifestation of the disease is myeloma bone disease (MBD), which is caused by increased osteoclastic bone resorption and decreased bone formation. The chemokine cytokine ligand 3 (CCL3) is a pro-inflammatory protein and chemokine that stimulates osteoclasts in MBD. However, little is known about the effect of CCL3 on osteoblasts (OB). Methods The OBs are induced from patients with MBD and healthy donors, cultured in vitro, and identified by histochemistry. The effects of CCL3 and CCL3 antibody on the OBs in vitro are observed. The CCL3 receptor (CCR1), osteocalcin (OCN), runt-related transcription factor 2 (Runx2), and osterix (Osx) are detected using flow cytometry, enzyme-linked immunosorbent assay, and real-time PCR. Results Proliferation and osteogenic potential of the OB in patients with MBD are suppressed. Moreover, the CCR1 expression is significantly higher in patients with MBD than in normal controls. The OCN level, quantity of calcium nodules, and Runx2 and Osx levels decrease after CCL3 stimulation, which indicates that CCL3 inhibits OB function. Furthermore, CCL3 antibody partially restores OB activity through the upregulation of the OCN, Runx2, and Osx. Conclusions CCL3 contributes to the OB/OC imbalance by inhibiting OB differentiation and function in MBD.